Bioatla Inc (BCAB) FinancialsBCABBioatla Inc

Evaluating the bottom line, Bioatla Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 3.49%, while the net margin is 6.95%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BCAB converts its operational activities into shareholder value.

In the context of the broader market, BCAB competes directly with industry leaders such as CHGA and CRIS. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BCAB's gross margin of 100.00% stands against CHGA's N/A and CRIS's N/A. Such benchmarking helps identify whether Bioatla Inc is trading at a premium or discount relative to its financial performance.

Bioatla's financial performance shows ongoing struggles with a net income loss of -$6.34 million in Q1 2026 and a gross margin of 100% only in select quarters, indicating inconsistent revenue generation. The company has reported a total revenue of $11 million in Q3 2024 but has not generated significant revenue in subsequent quarters, leading to a price-to-sales ratio of 0.615.